Immunovant (IMVT) Competitors $16.80 -0.01 (-0.04%) Closing price 02:41 PM EasternExtended Trading$16.80 +0.00 (+0.01%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMVT vs. SLNO, QGEN, MRNA, ASND, VTRS, BPMC, BBIO, VRNA, ROIV, and ELANShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), and Elanco Animal Health (ELAN). These companies are all part of the "medical" sector. Immunovant vs. Its Competitors Soleno Therapeutics Qiagen Moderna Ascendis Pharma A/S Viatris Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Soleno Therapeutics (NASDAQ:SLNO) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Which has preferable valuation & earnings, SLNO or IMVT? Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.62-18.75ImmunovantN/AN/A-$413.84M-$2.74-6.13 Which has more risk and volatility, SLNO or IMVT? Soleno Therapeutics has a beta of -2.63, suggesting that its share price is 363% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Do institutionals & insiders believe in SLNO or IMVT? 97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Comparatively, 5.9% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to SLNO or IMVT? In the previous week, Soleno Therapeutics had 7 more articles in the media than Immunovant. MarketBeat recorded 7 mentions for Soleno Therapeutics and 0 mentions for Immunovant. Soleno Therapeutics' average media sentiment score of 0.58 beat Immunovant's score of 0.00 indicating that Soleno Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Soleno Therapeutics Positive Immunovant Neutral Do analysts rate SLNO or IMVT? Soleno Therapeutics presently has a consensus target price of $107.10, suggesting a potential upside of 23.62%. Immunovant has a consensus target price of $38.33, suggesting a potential upside of 128.12%. Given Immunovant's higher probable upside, analysts plainly believe Immunovant is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Immunovant 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90 Is SLNO or IMVT more profitable? Soleno Therapeutics' return on equity of -77.52% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -77.52% -63.44% Immunovant N/A -80.60%-71.89% SummarySoleno Therapeutics beats Immunovant on 9 of the 13 factors compared between the two stocks. Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.87B$2.89B$5.49B$9.01BDividend YieldN/A2.64%5.39%4.09%P/E Ratio-6.1321.5627.4320.06Price / SalesN/A281.29398.25108.31Price / CashN/A41.4736.1356.90Price / Book4.047.518.085.67Net Income-$413.84M-$55.05M$3.16B$248.47M7 Day Performance2.53%3.16%2.12%2.90%1 Month Performance8.83%5.92%4.43%5.75%1 Year Performance-35.86%5.82%35.62%21.36% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMVTImmunovant1.5507 of 5 stars$16.800.0%$38.33+128.1%-36.6%$2.87BN/A-6.13120SLNOSoleno Therapeutics4.211 of 5 stars$83.78+0.6%$107.10+27.8%+117.0%$4.22BN/A-18.1330Insider TradeQGENQiagen3.818 of 5 stars$48.07+0.6%$49.40+2.8%+22.8%$10.69B$1.98B120.525,765Dividend AnnouncementMRNAModerna4.3803 of 5 stars$27.59+1.6%$46.61+68.9%-74.1%$10.67B$3.24B-3.165,800Options VolumeASNDAscendis Pharma A/S3.5544 of 5 stars$172.60+0.2%$220.67+27.8%+27.0%$10.55B$393.54M-27.481,017Analyst ForecastVTRSViatris3.2626 of 5 stars$8.93-0.9%$10.40+16.5%-10.5%$10.48B$14.74B-2.8232,000BPMCBlueprint Medicines1.7313 of 5 stars$128.18+0.1%$128.06-0.1%+16.2%$8.28B$562.12M-51.89640BBIOBridgeBio Pharma4.704 of 5 stars$43.18-3.7%$58.85+36.3%+71.9%$8.20B$221.90M-12.23400News CoverageAnalyst ForecastInsider TradeAnalyst RevisionHigh Trading VolumeVRNAVerona Pharma PLC American Depositary Share2.625 of 5 stars$94.58+0.8%$101.10+6.9%+482.7%$8.05B$42.28M-47.2930Positive NewsAnalyst ForecastROIVRoivant Sciences1.9356 of 5 stars$11.27-1.1%$17.50+55.3%+3.9%$7.66B$29.05M-45.08860ELANElanco Animal Health2.2433 of 5 stars$14.29flat$15.17+6.1%+5.1%$7.10B$4.44B19.319,000Analyst Forecast Related Companies and Tools Related Companies SLNO Competitors QGEN Competitors MRNA Competitors ASND Competitors VTRS Competitors BPMC Competitors BBIO Competitors VRNA Competitors ROIV Competitors ELAN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMVT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMVT Stock Alerts